Zhaoke Ophthalmology (an ophthalmic specialized pharmaceutical company in China) has signed the series B subscription agreement at an aggregate consideration of around US$ 145 million for ophthalmic’s medicine R&D and innovation. The transaction was led by Hillhouse COFL and TPG Asia and co-led by Loyal Valley Capital and other private equity firms.

VMS invested in its series A financing in 2019 and has participated in its Series B round financing.

If you would like to hear the latest updates on the Firm and the Fund, please feel free to contact our Investor Relations team at IR@VMSIG.COM.